In vitro antifungal susceptibility methods and clinical implications of antifungal resistance

References

• National Committee for Clinical Laboratory Standards. Refer-ence method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
   Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voricona-zole (UK-109,496) against opportunistic filamentous and di-morphic fungi and common and emerging yeast pathogens. J Gun Microbiol 1998; 36: 198–202.
   Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole 5CH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimor-phic fungi and yeasts. J Gun Microbiol 1998; 36: 2950–2956.
   Google Scholar
• Rex JH, Cooper CR, Merz WG, Galgiani JN, Anaissie El. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906–909.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fun-gemia. J Infect Dis 1989; 177: 425–430.
   Google Scholar
• Lozano-Chiu M, Nelson PW, Lancaster M, Pfaller MA, Rex JH. Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. J Gun Microbiol 1997; 35: 270–272.
   Google Scholar
• Rodriguez-Tudela JL, Martinez-Suarez JV. Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria. J Antimicrob Chem.other 1995; 35: 793–804.
   PubMedGoogle Scholar
• Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie El, Rex JH. Optimizing voriconazole susceptibility testing of Candida: ef-fects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J Gun Microbiol 1999; 37: 2755–2759.
   Google Scholar
• Rodriguez-Tudela JL, Martinez-Suarez JV, Dronda F, Chaves F, Valencia E. Correlation of in vitro susceptibility test results with in vivo response: a study of azole therapy in AIDS patients. J Antimicrob Chemother 1995; 35: 793–804.
   PubMedGoogle Scholar
• Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie El. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129–134.
   Google Scholar
• Revankar SG, Kirkpatrick WR, McAtee RK, et al. Interpreta-tion of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Gun Microbiol 1998; 36: 153–156.
   Google Scholar
• Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ. Quan-titation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Micro-biol 1999; 37: 3332–3337.
   Google Scholar
• Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantita-tion of Candida albicans ergosterol content improves the corre-lation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 2000; 44: 2081–2085.
   Google Scholar
• Man KA, Rustad TR, Rex JH, White TC. The trailing end point phenotype in antifungal susceptibility testing is pH depen-dent. Antimicrob Agents Chemother 1999; 43: 1383–1386.
   PubMedGoogle Scholar
• Barry AL, Pfaller MA, Brown SD, et al. Quality controls limits for broth microbiology susceptibility tests of ten antifungal agents. J Clin Microbial 2000; 38: 3457–3459.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Buschelman B, Bale MJ, et al. Multicenter com-parison of a colorimetric microdilution broth method with the reference macrodilutoion method for in-vitro susceptibility test of yeast isolates. Diagn Microbiol Infect Dis 1994; 19: 9–13.
   PubMedGoogle Scholar
• Pfaller MA, Vu Q, Lancaster M, et al. Multisite reproducibility of colorimetric broth microdilution method for antifungal sus-ceptibility testing of yeast isolates. J Clin Microbiol 1994; 32: 1625–1628.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Rodriguez-Tudela JL, Martinez-Suarez JV. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in-vitro testing of fluconazole-resistant and -susceptible isolates of Candida albi-cans. J Clin Microbiol 1995; 33: 3154–3158.
   PubMedGoogle Scholar
• To WK, Fothergill AW, Rinaldi MG. Comparative evaluation of macrodilution and Alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1995; 33: 2660–2664.
   Google Scholar
• Hawser SP, Norris H, Jessup CJ, Ghannoum MA. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfopheny1)-5-[(phenyl-amino)-carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol 1998; 36: 1450–1452.
   PubMed Web of Science ®Google Scholar
• Davey KG, Szekely A, Johnson EM, Warnock DW. Compari-son of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 1998; 42: 439–444.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Pfaller M, Messer SA, et al. Multicenter comparison of the Sensititre Yeast One Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J Clin Microbiol 1999; 37: 591–595.
   Google Scholar
• Pfaller MA, Arikan S, Lozano-Chiu M, et al. Clinical evalua-tion of the ASTY colorimetric microdilution panel for antifun-gal susceptibility testing. J Clin Microbiol 1998; 36: 2609–2612.
   Google Scholar
• Davey KG, Holmes AD, Johnson EM, Warnock DW. Com-parative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. J Clin Microbiol 1998; 36: 926–930.
   PubMedGoogle Scholar
• Witthuhn F, Toubas D, Beguinot I, et al. Evaluation of the Fungitest kit by using strains from human immunodificiency virus-infected patients: study of azole drug susceptibility. J Clin Microbiol 1999; 37: 864–866.
   PubMedGoogle Scholar
• Odds FC, Vranckx L, Woestenborghs F. Antifungal susceptibil-ity testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 1995; 39: 2051–2060.
   Google Scholar
• Pfaller MA, Messer SA, Coffmann S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole, D0870. J Clin Microbiol 1995; 33: 1094–1097.
   Google Scholar
• Rodriguez-Tudela JL, Berenguer J, Martinez-Suarez JV, Sanchez R. Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in-vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. An-timicrob Agents Chemother 1996; 40: 1998–2003.
   Google Scholar
• Ghannoum MA, Ibrahim AS, Fu Y, Shafiq MC, Edwards JE, Criddle RS. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992; 30: 2881–2886.
   PubMed Web of Science ®Google Scholar
• Sanati H, Messer SA, Pfaller M, et al. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J Clin Microbiol 1996; 34: 1280–1282.
   PubMedGoogle Scholar
• Pfaller MA, Dupont B, Kobayashi GS, et al. Standardized susceptibility testing of fluconazole: an international collabora-tive study. Antimicrob Agents Chemother 1992; 36: 1805–1809.
   PubMedGoogle Scholar
• Barry AL, Brown SD. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol 1996; 34: 2154–2157.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Turner TM, Fothergill AW, et al. Flucona-zole disk diffusion susceptibility testing of Candida species. J Clin Microbiol 1998; 36: 3429–3432.
   PubMed Web of Science ®Google Scholar
• Lozano-Chiu M, Nelson PW, Paetznick VL, Rex J. Disk diffu-sion for determining susceptibilites of Candida spp. to MK-0991. J Clin Microbiol 1999; 36: 1625–1627.
   Google Scholar
• Espinel-Ingroff A. E test for antifungal susceptibility testing of yeasts. Diagn Microbiol Infect Dis 1994; 19: 217–220.
   PubMed Web of Science ®Google Scholar
• Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Com-parison of E test and National Committee for Clinical Labora-tory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535–540.
   PubMed Web of Science ®Google Scholar
• Chen SCA, O'Donnell ML, Gordon S, Gilbert GL. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique. J Antimicrob Chemother 1996; 37: 265–273.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Pfaller MA, Erwin ME, Jones RN. Interlab-oratory evaluation of E test method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using casitone agar and solidified RPMI 1640 medium with 2% glucose. J Gun Microbiol 1996; 34: 848–852.
   Google Scholar
• Pfaller MA, Messer SA, Bolmstrom A, Odds FC, Rex JH. Multisite reproducibility of the E test method for antifungal susceptibility of yeast isolates. J Gun Microbiol 1996; 34: 1691–1693.
   Google Scholar
• Warnock DW, Johnson EM, Rogers TRF. Multi-centre evalua-tion of the E test method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimi-crob Chemother 1998; 4/ 321–331.
   Google Scholar
• Wanger A, Mills K, Nelson PW, Rex JH. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility test-ing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520–2522.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314–319.
   Google Scholar
• Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Gun Microbiol 1997; 35: 139–143.
   Google Scholar
• Espinel-Ingroff A, Kerkering TM. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J Gun Microbiol 1991; 29: 393–394.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Refer-ence method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard. Document M38-P. Wayne, PA: National Committee for Clini-cal Laboratory Standards, 1998.
   Google Scholar
• Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42: 282–288.
   Google Scholar
• Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364–1368.
   PubMed Web of Science ®Google Scholar
• Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in vitro susceptibility test-ing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401–414.
   PubMed Web of Science ®Google Scholar
• Kitahara M, Seth VK, Medoff G, Kobayashi GS. Antimicro-bial susceptibility testing of six clinical isolates of Aspergillus. Antimicrob Agents Chemother 1976; 9: 908–914.
   PubMedGoogle Scholar
• Bezjak V. Standardization of a hyphal inoculum of aspergilli for amphotericin B susceptibility testing. J Gun Microbiol 1985; 21: 509–512.
   Google Scholar
• Manavathu EK, Cutright J, Chandrasekar PH. Comparative study of susceptibilities of germinated and ungenninatekl conidia of Aspergillus fumigatus to various antifungal agents. J Gun Microbiol 1999; 37: 858–861.
   Google Scholar
• Guarro J, Llop C, Aguilar C, Pujol I. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob Agents Chemother 1997; 41: 2760–2762.
   PubMed Web of Science ®Google Scholar
• Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin MK-0991 (L-743,872): Efficacy in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother 1997; 41: 2333–2338.
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Heath IB, Marrinan J, Dreikom S, Onishi J, Douglas C. Morphological effects of lipopeptides against As- 0 2000 ISHAM, Medical Mycology, 38, Suppl. I, 293–304 apergillus fumigatus correlate with activities against (1,3)-I3-D-glucan synthase. Antimicrob Agents Chemother 1994; 3& 1480–1489.
   Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326–2332.
   PubMed Web of Science ®Google Scholar
• Szekely A, Johnson EM, Warnock DW. Comparison of E-test and broth microdilution methods for antifungal drug suscepti-bility testing of molds. J Gun Microbiol 1999; 37: 1480–1483.
   Google Scholar
• Espinel-Ingroff A. E test for antifungal susceptibility testing of opportunistic filamentous fungi: A comparison with the NC-CLS M38-P method. Program and Abstracts of the Annual Meeting of the ASM. Washington DC: American Society for Microbiology, 1996; Abstract C26.
   Google Scholar
• Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997; 41: 1124–1126.
   Google Scholar
• Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17: 573–575.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole and amphotericin B against filamen-tous fungi. J Antimicrob Chemother 1998; 4/. 741–745.
   Google Scholar
• Verweij PE, van den Bergh MFQ, Rath PM, dePaw BE, Voss A, Meis JFGM. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol 1999; 37: 1606–1609.
   PubMed Web of Science ®Google Scholar
• Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Gun Microbiol 1999; 37: 2343–2345.
   Google Scholar
• Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12 year experience and review of the literature. Clin Infect Dis 1998; 26: 1092–1097.
   Google Scholar
• Aguilar C, Pujol I, Sala J, Guarro J. Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother 1998; 4/ 1601-1604.
   Google Scholar
• Aguilar C, Pujol I, Guano J. In vitro antifungal susceptibilities of Scopulariopsis isolates. Antimicrob Agents Chemother 1999; 43: 1520–1522.
   PubMed Web of Science ®Google Scholar
• Li R-K, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces detmatitidis, Coccid-ioides immitis, and Histoplasma capsulatum, Antimicrob Agents Chemother 2000; 44: 1734–1736.
   Google Scholar
• Rex J, Pfaller MA, Galgiani JN, et al. Development of interpre-tive breakpoints for antifungal susceptibility testing: conceptual frame work and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235–247.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplanta-tion and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274–1277.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidiasis. J Antimicrob Chemother 1995; 35: 103–114.
   Google Scholar
• Neuman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994; 19: 684–686.
   PubMedGoogle Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308–328.
   Google Scholar
• Conly J, Rennie R, Johnson J, Farah S, Hellman L. Dissemi-nated candidiasis due to amphotericin-B-resistant Candida albi-cans. J Infect Dis 1992; 165: 761–764.
   Google Scholar
• Vazquez JA, Lundstrum T, Dembry L, et al. Invasive Candida guilliermondii infection: in vitro susceptibility studies and molec-ular analysis. Bone Marrow Trans 1995; 16: 849–853.
   PubMedGoogle Scholar
• Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Ampho-tericin B resistant yeast infections in severely immunocompro-misekl patients. Am J Med 1955; 84: 826–832.
   Google Scholar
• Fryberg M, Oehlschlager AC, Unrau AM. Sterol biosynthesis in antibiotic sensitive and resistant Candida. Arch Biochem Biophys 1975; 173: 171–177.
   Google Scholar
• Hitchcock CA, Barrett-Bee KJ, Russell NJ. The lipid composi-tion and permeability to azole of an azole and polyene-resistant mutant of Candida albicans. J Med Vet Mycol 1987; 25: 29–37.
   PubMed Web of Science ®Google Scholar
• Hitchcock CA. Resistance of Candida albicans to azole antifun-gal agents. Biochem Soc Trans 1993; 21: 1039–1047.
   PubMedGoogle Scholar
• Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resis-tance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995; 39: 1696–1699.
   Google Scholar
• Diamond RD. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis 1991; 13: 480–486.
   PubMedGoogle Scholar
• Just G, Steinheimer D, Schnellbach B, et al. Change of causative organisms under antifungal treatment in immunosup-pressed patients with HIV infections. Mycoses 1989; 32 (Suppl. 2): 47–51.
   Google Scholar
• Holt RJ, A7Mi A. Miconazole resistant Candida. Lancet 1978; 1: 50–51.
   PubMedGoogle Scholar
• Ghannoum MA, Rex JR, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Gun Microbiol 1996; 34: 489–495.
   Google Scholar
• Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrobiol Agents Chemother 1993; 37: 1847–1849.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Kauffman C, Sobel JD, Perri MB, Zervos MJ. A comparative study of in-vitro susceptibility of Candida species. Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Septem-ber 29—October 3,1991. Washington DC: American Society for Microbiology, 1991, Abstract 483.
   Google Scholar
• Vazquez JA, Lynch M, Boikov D, Sobel JD. Incidence of in-vitro antifungal cross resistance among fluconazole-resistant Candida albicans and T. glabrata isolates. Program and Ab-stracts of the 33rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, September 11–18, 1995. Alexandria, VA: Infectious Diseases Society of America, 1995, Abstract 344.
   Google Scholar
• Horsburgh CR, Kirkpatrick CH. Long term therapy of chronic mucocutaneous candidiasis with ketoconazole experience with twenty-one patients. Am J Med 1983; 74 (Suppl. 1B): 23–29.
   Google Scholar
• Ryley JF, Wilson RG, Barrett-Bee KJ. Azole resistance in Candida albicans. Sabouraudia 1984; 2/ 53–63.
   Google Scholar
• Odds FC. Resistance to azole-derivative antifungals. J Antimi-crob Chemother 1993; 31: 463–471.
   PubMed Web of Science ®Google Scholar
• Hennequin C, Labenne M, Benkerrou M, Hambourg M. Flu-conazole-resistant Candida albicans in an immunocompetent child. Clin Infect Dis 1994; 19: 1179–1180.
   PubMedGoogle Scholar
• Goff DA, Koletar SL, Buesching WJ, Bamishan J, Fass RJ. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis 1995; 20: 77–83.
   Google Scholar
• Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with Human Immunodeficiency Virus. Clin Infect Dis 1996; 2/ 726–727.
   Google Scholar
• Korting HC, 011ert M, Georgii A, Froschl M. In-vitro suscepti-bilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with Human Immunodeficiency Virus. J Clin Microbiol 1988; 26: 2626–2631.
   Google Scholar
• Koletar SL, Weed HG, Ramundo MB. Thrush unresponsive to treatment with fluconazole in HIV-infected patients. 1st Na-tional Conference on Human Retroviruses, January 26–28,1994. Alexandria, VA: Foundation for Retrovirology, 1994, Abstract 35.
   Google Scholar
• Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in Human Immunodeficiency Virus-infected patients. J Infect Dis 1996; 173: 219–225.
   PubMed Web of Science ®Google Scholar
• Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS develop-ing resistance to fluconazole. J Clin Microbiol 1993; 31: 2933–2937.
   Google Scholar
• Million L, Manteaux A, Reboux G, et al. Fluconazole-resistant recurrent oral candidiasis in Human Immunodeficiency Virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994; 32: 1115–1118.
   PubMed Web of Science ®Google Scholar
• Ng TTC, Denning DW. Fluconazole resistance in Candida in patients with AIDS: a therapeutic approach. J Infect 1994; 26: 117–125.
   Google Scholar